Overview
Thomas Clozel is CEO and Co-founder at OWKIN [1][3], a position held since June 2016 [3]. Clozel is a Medical Doctor focused on bringing the first AI physician-scientist connecting drug development to care [2]. Beyond OWKIN, Clozel holds concurrent roles as non-operational cofounder and Board Director at Bioptimus [4], non-operational cofounder at Cure51 [7], and serves as a venture advisor at Sofinnova Partners [9], an advisor to GRACE [10], a member of the Board of Directors at Université Paris-Saclay [6], and an advisor to EQT Group [8]. Clozel also participates in the XPRIZE Brain trust [5]. Clozel completed a research fellowship in Hematology-oncology at Joan & Sanford I. Weill Medical College of Cornell University from 2009 to 2011 [11] and a clinical rotation in the Neurology Department at Icahn School of Medicine at Mount Sinai in 2006 [12].
Profile introduction
I am a creative and dynamic Medical Doctor focused on bringing the first Ai physician-scientist connecting drug development to care
Career history
- CEO and Co-founderJun 2016 to presentOWKIN
- Non operational cofounder and Board DlrectorFeb 2024 to presentBioptimus
- Brain trustJun 2024 to presentXPRIZE
- Member Board of DirectorsApr 2024 to presentUniversité Paris-Saclay
- Non operational cofounderMar 2024 to presentCure51
- AdvisorJan 2025 to presentEQT Group
- Venture advisorAug 2022 to presentSofinnova Partners
- AdvisorMar 2023 to presentGRACE
Education
- research fellowship, Hematology-oncology2009 - 2011Joan & Sanford I. Weill Medical College of Cornell University
- Clinical rotation, Neurology Department2006 - 2006Icahn School of Medicineat Mount Sinai
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.